ArticlePloS one2016

Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.

Chunxiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.